These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28293280)

  • 21. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis.
    Black CJ; Burr NE; Camilleri M; Earnest DL; Quigley EM; Moayyedi P; Houghton LA; Ford AC
    Gut; 2020 Jan; 69(1):74-82. PubMed ID: 30996042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome.
    Matsueda K; Harasawa S; Hongo M; Hiwatashi N; Sasaki D
    Digestion; 2008; 77(3-4):225-35. PubMed ID: 18667823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome.
    Khalilian A; Ahmadimoghaddam D; Saki S; Mohammadi Y; Mehrpooya M
    Biopsychosoc Med; 2021 Feb; 15(1):3. PubMed ID: 33536043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J).
    Kanazawa M; Drossman DA; Shinozaki M; Sagami Y; Endo Y; Palsson OS; Hongo M; Whitehead WE; Fukudo S
    Biopsychosoc Med; 2007 Mar; 1():6. PubMed ID: 17371576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial.
    Bensoussan A; Kellow JE; Bourchier SJ; Fahey P; Shim L; Malcolm A; Boyce P
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1946-54.e1. PubMed ID: 26133902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
    Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of 5-HT4 Receptor Agonist Minesapride for Irritable Bowel Syndrome with Constipation in a Randomized Controlled Trial.
    Fukudo S; Nakamura M; Hamatani T; Kazumori K; Miwa H
    Clin Gastroenterol Hepatol; 2021 Mar; 19(3):538-546.e8. PubMed ID: 32184185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Solifenacin on Irritable Bowel Syndrome With Diarrhea: Open-label Prospective Pilot Trial.
    Fukushima Y; Suzuki H; Matsuzaki J; Kiyosue A; Hibi T
    J Neurogastroenterol Motil; 2012 Jul; 18(3):317-23. PubMed ID: 22837880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study.
    Brenner DM; Sayuk GS; Gutman CR; Jo E; Elmes SJR; Liu LWC; Cash BD
    Am J Gastroenterol; 2019 Sep; 114(9):1502-1511. PubMed ID: 31356229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
    Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S
    J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1.
    Shiotani A; Kusunoki H; Ishii M; Imamura H; Manabe N; Kamada T; Hata J; Merchant JL; Haruma K
    Neurogastroenterol Motil; 2015 Jan; 27(1):82-91. PubMed ID: 25428414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Ki Cha B; Mun Jung S; Hwan Choi C; Song ID; Woong Lee H; Joon Kim H; Hyuk J; Kyung Chang S; Kim K; Chung WS; Seo JG
    J Clin Gastroenterol; 2012 Mar; 46(3):220-7. PubMed ID: 22157240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of Chinese medicine JCM-16021 for diarrhea-predominant irritable bowel syndrome: study protocol for a multi-center, randomized, double-blind, placebo controlled clinical trial.
    Zheng Y; Ching J; Cheng CW; Lam WC; Chan KL; Zhang X; Lam PY; Wu XY; Zhong LLD; Cao PH; Lo CW; Cheong PK; Lin Z; Koh M; Wu J; Bian ZX
    Chin Med; 2021 Nov; 16(1):117. PubMed ID: 34774080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.
    Chey WD; Lembo AJ; Rosenbaum DP
    Am J Gastroenterol; 2017 May; 112(5):763-774. PubMed ID: 28244495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Importance of diarrhea in evaluating constipation in irritable bowel syndrome clinical studies.
    Basseri RJ; Kunkel D; Low K; Conklin JL; Pimentel M
    J Clin Gastroenterol; 2011 Oct; 45(9):790-3. PubMed ID: 21301356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS.
    Tack J; Schumacher K; Tonini G; Scartoni S; Capriati A; Maggi CA;
    Gut; 2017 Aug; 66(8):1403-1413. PubMed ID: 27196574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D.
    Eswaran SL; Chey WD; Han-Markey T; Ball S; Jackson K
    Am J Gastroenterol; 2016 Dec; 111(12):1824-1832. PubMed ID: 27725652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized controlled and long-term linaclotide study of irritable bowel syndrome with constipation patients in Japan.
    Fukudo S; Miwa H; Nakajima A; Haruma K; Kosako M; Nakagawa A; Akiho H; Yamaguchi Y; Johnston JM; Currie M; Kinoshita Y
    Neurogastroenterol Motil; 2018 Dec; 30(12):e13444. PubMed ID: 30136447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.